MHC class I tetramers have been used extensively to directly identify and characterize antigen specific CD8 T-cells in the setting of infection, malignancy and graft versus host disease. Producing MHC class I tetramers requires the purification of recombinantly expressed class I heavy chain and beta-2-microglobulin, in vitro folding of these proteins with antigenic peptides, enzymatic biotinylation and complex formation with fluorescently labeled streptavidin. We have established a protocol for the reproducible and reliable production of high quality tetramers using the following MHC class I proteins: HLA A1, A2, A3, A11, B7, B8, B27, B35 and H2-Kd, Kb, Db and Ld. The HLA-tetramer core will generate MHC class I tetramers for projects described in this program. The core will incorporate quality control assays at all major steps during tetramer production and will test the specificity and sensitivity of tetramers when CD8 T-cell lines are available. MHC class I tetramer production is time consuming and requires significant technical training and expertise. The HLA-tetramer core will greatly facility the production of tetramers for the projects of this program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA023766-24A1
Application #
6606703
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-05-08
Project End
2007-02-28
Budget Start
Budget End
Support Year
24
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Moskowitz, Craig H (2018) Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily. Blood Adv 2:821-824
Kim, Seong Jin; Huang, Yao-Ting; Foldi, Julia et al. (2018) Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients. Transpl Infect Dis 20:e12881
Maslak, Peter G; Dao, Tao; Bernal, Yvette et al. (2018) Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv 2:224-234
DeFilipp, Zachariah; Peled, Jonathan U; Li, Shuli et al. (2018) Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv 2:745-753
Haak, Bastiaan W; Littmann, Eric R; Chaubard, Jean-Luc et al. (2018) Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT. Blood 131:2978-2986
Boudreau, Jeanette E; Hsu, Katharine C (2018) Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned. Trends Immunol 39:222-239
Lin, Richard J; Ho, Caleb; Hilden, Patrick D et al. (2018) Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol :
Malard, Florent; Labopin, Myriam; Cho, Christina et al. (2018) Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. J Hematol Oncol 11:127
Luduec, Jean-BenoƮt Le; Kudva, Anupa; Boudreau, Jeanette E et al. (2018) Novel multiplex PCR-SSP method for centromeric KIR allele discrimination. Sci Rep 8:14853
Shah, Gunjan L; Moskowitz, Craig H (2018) Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood 131:1689-1697

Showing the most recent 10 out of 452 publications